Oncology specialists from around the world will come together for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting to discuss the latest developments in cancer care, research, technology and education.
The meeting will feature over 200 sessions complementing this year’s theme, “The Art and Science of Cancer Care: From Comfort to Cure.” More than 30,000 people are expected to attend the meeting taking place in Chicago and online May 31 – June 4, 2024.
UCSF experts will discuss research findings in an array of cancer specialties. They will share best practices in educational sessions highlighting innovate treatment strategies.
In addition, UCSF’s Eric J. Small, MD, FASCO, has been elected to serve as ASCO’s president for the term beginning in June 2025. Small will take office as president-elect immediately following the ASCO Annual Business Meeting on June 3. In addition to being a long-time ASCO member and volunteer, Small is co-leader of the UCSF Prostate Cancer Program and deputy director and chief scientific officer of the UCSF Helen Diller Family Comprehensive Cancer Center.
UCSF clinicians and researchers receiving awards from ASCO at this year’s meeting include: • Young Investigator Awards – William S. Chen, MD, Lindsey M. Draper, MD, Kelsey Natsuhara, MD, Michael P. Randall, MD, and Noah Younger, MD, PhD • Annual Meeting Merit Awards – Kirkpatrick Fergus, MD, Mulki Mehari, BA, and Ali Sabbagh, MD
Leading UCSF Presentations (All times Central):
Friday, May 31, 6:30 p.m. – 8:00 p.m.
Hope Rugo, MD, a medical oncologist, Winterhof Family Endowed Professor in Breast Cancer, and director of Breast Oncology Trials and Clinical Education at UCSF leads a panel of breast cancer experts discussing treatment options for patients with triple negative and HR-positive/ HER2-negative breast cancer in the session “Transforming Metastatic Breast Cancer Management: Harnessing the Power of Antibody-Drug Conjugate Therapies.” These patients have limited treatment options after the development of endocrine resistance. This dearth of options is particularly acute for Black women and other marginalized patients, and results in treatment disparities. The panelists will lead participants through a discussion of treatment with antibody-drug conjugates, adverse event management, and strategies to foster equitable care of patients with metastatic breast cancer.
Saturday, June 1, 8:00 a.m. – 9:00 a.m.
Katy K. Tsai, MD, a medical oncologist and UCSF associate professor of Medicine, leads a cased-based panel, “Navigating Melanoma Management From Early Stages to Post-Adjuvant Therapy” which will be live streamed as well as presented in person. The panel will address multidisciplinary care for patients with stage II melanoma, including the role of sentinel lymph node biopsy, neoadjuvant and adjuvant options, assessment of pathological response, and management of locoregional relapse following anti-PD1 immunotherapy.
Saturday, June 1, 8:00 a.m. – 9:30 a.m.
Katherine C. Fuh, MD, PhD, a gynecologic oncologist and associate professor in the UCSF department of Obstetrics, Gynecology and Reproductive Sciences, presents “AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer” from 8:28 a.m. – 8:34 a.m. during a rapid oral abstract session focusing on gynecological cancer. Abstract LBA5515 (The full, final text of this abstract will be available on the day of presentation and online in the June 10, 2024, issue of the Journal of Clinical Oncology.)
Saturday, June 1, 3:00 p.m. – 4:30 p.m. Benjamin Joshua Lerman, MD, MS, UCSF clinical fellow, presents “Longitudinal tumor-wide sampling of glioblastoma reveals diverse genomic drivers of the earliest clonal expansion at diagnosis and recurrence” from 3:12 p.m. – 3:24 p.m. at the clinical science symposium “Advancing Trial Design: Illuminating Tumor Evolution in Central Nervous System Cancer.” Much of therapy resistance in glioblastoma (GBM) is attributed to intratumoral heterogeneity, but few genomic studies go beyond analyzing single tumor samples per patient. Lerman and his colleagues used a spatially oriented, whole tumor sampling approach to obtain 43 biopsies from 3 GBMs at diagnosis and recurrence. Whole-tumor sampling at both diagnosis and recurrence identified a diversity of genomic drivers and deeper and more complex genetic roots of individual GBM than previously seen in single-biopsy studies. Abstract 2009
Saturday, June 1, 3:00 p.m. – 4:15 p.m.
Matthew A. Gubens, MD, MS, FASCO, a thoracic medical oncologist and UCSF professor of Medicine, presents “Metastatic Non–Small Cell Lung Cancer with Oncogene Addiction/Driver Mutation (not EGFR)” during the education session “Advanced Lung Cancer: State-of-the-Art Approaches and Insights.” Gubens also serves as a panelist during the session which will review current state-of-the-art approaches and recent advances in the care of patients with metastatic small cell and non-small cell lung cancer. The participants will also discuss strategies for selecting an appropriate therapy for patients with different disease subtypes.
Sunday, June 2, 9:45 a.m. – 11:00 a.m.
Kevan M. Shokat, PhD, UCSF professor of Cellular and Molecular Pharmacology and AACR Academy Fellow, presents “The Story of KRAS-Directed Therapy from Bench to Bedside: A Roadmap for Success?” from 9:49 a.m. – 10:07 a.m. during the special session “ASCO/AACR Joint Session: Drugging the “Undruggable” Target: Successes, Challenges, and the Road Ahead.” Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human cancer, and are generally associated with poor response to standard therapies. While K-Ras has been an obvious drug target, the use of traditional drug discovery strategies has been a major challenge. Shokat’s talk will discuss experience with the first targeted therapy based on Farnesyl Transferase Inhibition to target Ras mutant tumors. He will discuss the biochemical basis for activation of K-Ras through mutation of the G12 position and the discovery of the first small molecules that irreversibly bind to the most common K-Ras somatic oncogenic mutant in lung cancer, K-Ras (G12C). He also will discuss the evolution of the K-Ras (G12C) inhibitors into highly selective drug candidates for K-Ras (G12D) mutant tumors.
Sunday, June 2, 2024, 11:30 a.m. – 1:00 p.m.
Zoe Quandt, MD, MS, an endocrinologist and assistant professor in the UCSF department of Endocrinology presents “HLA associations with immunotherapy related endocrine toxicity,” from 12:00 p.m. – 12:06 p.m. during the rapid oral abstract session on developmental therapeutics and immunotherapy. Endocrine immune related adverse events (irAEs) such as thyroid dysfunction, diabetes mellitus and hypophysitis, are caused by treatment with immune checkpoint inhibitors (ICIs) and are largely irreversible, posing a burden to cancer patients. Quandt’s study included 6300 patients from multiple international centers who were treated with ICIs for multiple cancer types. In her talk, Quandt will report on the most common endocrine irAEs as well as human leukocyte antigen types associated with endocrine irAEs. Abstract 2516
Monday, June 3, 8:00 a.m. – 11:00 a.m. John Frederick de Groot, MD, a neuro-oncologist division chief of the Neuro-Oncology in the UCSF department of Neurological Surgery, discusses his study, “Evaluation of VAL-083 in GBM AGILE, a phase 3 registration platform trial for newly diagnosed and recurrent glioblastoma,” from 9:24 a.m. – 9:36 a.m. during an oral abstract session on central nervous system tumors. GBM AGILE is an efficient and effective model for phase 3 drug development. VAL-083 (VAL) is a DNA targeting agent that, independent of O6-methylguanine DNA methyltransferase promoter methylation status, targets the N7 position of guanine residues and facilitates inter-strand DNA crosslinks, leading to DNA double-strand breaks and cell death. GBM AGILE evaluated this agent in less time, at lower cost, and with fewer patients than typical registration trials and is currently evaluating several other arms. Final results will be presented at the meeting. Abstract 2005 Sunday, June 3, 1:15 p.m. – 2:45 p.m.
Rahul Raj Aggarwal, MD, a genitourinary oncologist and UCSF professor of Medicine, presents “Phase 1b study of tarlatamab in de novo or treatment-emergent neuroendocrine prostate cancer (NEPC)” at 1:33 p.m. during a rapid oral abstract session on prostate, testicular and penile cancers. NEPC is an aggressive form of prostate cancer with poor prognosis and no standard treatment approach. NEPC can be characterized by late, treatment-emergent transformation from adenocarcinoma to high-grade neuroendocrine carcinoma (NEC), in 10–15% of mCRPC patients. Aggarwal reports primary analysis data of tarlatamab in NEPC. Findings from this phase 1 study of tarlatamab in patients with NEPC demonstrated manageable safety with encouraging anti-tumor activity in DLL3 expressing NEPC. Abstract 5012
Monday, June 3, 4:30 p.m. – 6:00 p.m.
Steven Z. Pantilat, MD, Kates-Burnard and Hellman Distinguished Professor in Palliative Care and director of UCSF’s Palliative Care Program, will participate in the clinical science symposium on symptom science and palliative care, “Hope Beyond a Cure.” He will speak from 4:54 p.m. – 5:06 p.m. The session will begin with a foundational presentation on the session topic to set the stage for the abstracts to follow. Abstract presenters summarize research findings, while discussants place the abstracts in the appropriate context with a focus on how the findings apply to clinical practice.